Sorafenib effective in patients with non-small cell lung cancer, but low survival rates reported
Tuesday, January 10, 2012 - 05:30
in Health & Medicine
Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but survival rates were reportedly "unsatisfactory," according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and Personalized Medicine, held Jan. 8-11, 2012.